Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response-guided treatment duration study of telaprevir + peginterferon alfa-2a + ribavirin in treatment-naive genotype 1 chronic hepatitis C
2008-003836-39Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of telaprevir in hepatitis C virus infection (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Proportion of randomized subjects achieving sustained viral response. Started Aug 2008; status: completed.
02
Drugs
telaprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2008-003836-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003836-39.